Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-12-06
2005-12-06
Parkin, J. S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S188100, C424S208100, C435S343100, C530S388750
Reexamination Certificate
active
06972126
ABSTRACT:
This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+cell, but not a T cell-tropic isolate of HIV-1 to a CD4+cell; and agents determined to be capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4+cell, but not a macrophage-tropic primary isolate of HIV-1 to a CD4+cell. This invention also provides: agents capable of specifically inhibiting the fusion of a macrophage tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1; and agents capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 with a CD4+cell susceptible to infection by a T cell-tropic isolate of HIV-1. The agents include but are not limited to antibodies. This invention further provides: methods of inhibiting fusion of a macrophage-tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1 which comprises contacting the CD4+cell with an amount of an agent capable of specifically inhibiting such fusion so as to thereby inhibit such fusion; and methods of inhibiting fusion of a T cell-tropic isolate of HIV-1 with a CD4+cell susceptible to infection by a T cell-tropic isolate of HIV-1 which comprises contacting the CD4+cell with an amount of an agent capable of specifically inhibiting such fusion so as to thereby inhibit such fusion.
REFERENCES:
patent: WO9516789 (1995-06-01), None
Hirsch, M. S., et al., 1997, “Antiretorviral therapy”, inAIDS: Biology, Diagnosis, Treatment and Prevention, fourth edition, V. T. DeVita, Jr., et al., eds., Lippincott-Raven Publishers, pp. 495-507.
Vanini, S., et al., 1992, “Discrete regions of HIV-1 gp41defined by syncytia-inhibiting affinity-purified human antibodies”, AIDS 7:167-174.
Verrier, F. C., et al., 1997, “Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate”, Proc. Natl. Acad. Sci. USA 94:9326-9331.
Frazer, J. K., and J. D. Capra, 1999, “Immunoglobulins: structure and function”, inFundamental Immunology, Fourth Edition, W. E. Paul, ed., Lippincott-Raven Publishers, Philadelphia, pp. 37-74.
Max, E. E., 1999, “Immunoglobulins: structure and function”, inFundamental Immunology, Fourth Edition, W. E. Paul, ed., Lippincott-Raven Publishers, Philadelphia, pp. 111-182.
Mateu, M. G., et al., 1992, “Non-additive effects of multiple amino acid substitutions on antigen-antibody recognition”, European J. Immunol. 22(6):1385-9.
Alexander, H., et al., 1992, “Altering the antigenicity of proteins”, Proc. Natl. Acad. Sci. USA 89(8): 3352-6.
Camerini, D., et al., (1990) “A CD4 Domain Important for HIV-Mediated Syncytium Formation Lies outside the Virus Binding Site”, Cell, vol. 60, No. 5, 747-754 (Exhibit 1).
Clapham, P.R., et al., (1989) “Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells.” Nature, vol. 337, No. 6205, 368-370 (Exhibit 2).
Dragic, et al., (1992)“Complementation of Murine Cells for Human Immunodeficiency Virus Envelope/CD4-Mediated Fusion in Human-Murine Heterokaryons”, Journal of Virology, vol. 66, No. 8, 4794-4802 (Exhibit 3).
Freed, E. O., et al., (1991) “Identification of Conserved Residues in the Human Immunodeficiency Virus Type 1 Principal Neutralizing Determinant That Are Involved in Fusion” AIDS Research and Human Retroviruses, vol. 7, No. 10, 807-811 (Exhibit 4).
Harouse, J. M. et al., (1991) “Inhibition of Entry of HIV-1 in Neural Cell Lines by Antibodies Against Galactosyl Ceramide” Science, vol. 253, No. 5017, 320-323 (Exhibit 5).
Mittler, R.S., et al., (1989) “Synergism Between HIV gp120 and gp120-specific Antibody in Blocking Human T Cell Activiation.”, Science, vol. 245, No. 4924, 1380-1382 (Exhibit 6).
Travis, B.M., et al., (1992 “Functional Roles of the V3 Hypervariable Region of HIV-1 gp160 in the Processing of gp 160 and in the Formation of Syncytia in CD4-positive Cells”, Virology, Col. 186, No. 1, 313-317 (Exhibit 7).
Weinhold, K.J., et al., (1989) “HIV-1 gp120-Mediated Immune Suppression and Lymphocyte Destruction in the Absence of Viral Infection.” Journal of Immunology, vol. 142, No. 9, 3091-3097 (Exhibit 8).
Chams, et al., (1992) “Simple Assay To Screen for Inhibitors of Interaction Between the Human Immunodeficiency Virus Envelope Glycoprotein and Its Cellular Receptor, CD4”Antimicrobial Agents and Chemotherapy36(2):262-272.
Dimitrov, D.S., et al., (1991) “Initial Stages of HIV-1 Envelope Glycoprotein-Mediated Cell Fusion Monitored by a New Assay Based on Redistribution of Fluorescent Dyes”AIDS Res.&Human Retroviruses7(10):799-805.
Dragic, et al., (1993) “Different Requirement for membrane Fusion Mediated by the Envelopes of Human Immunodeficiency”Journal of Virology67(2):2355-2359.
Fouchier, et al., (1994) “HIV-1 Macrophage Tropism Is Determined at Multiple Levels of the Viral Replication Cycle”Journal of Clinical Investigation94:1806-1814.
Keller, P.M., et al., (1977) “A Fluorescence Enhancement Assay of Cell Fusion”J. Cell Sci.28:167-177 (Exhibit 1).
Mitsuya, H., et al., (1985) “Protection of T Cells Against Infectivity and Cytopathic Effect of HTLV-III In Vitro, in Miwa, et al. Eds., Retroviruses in Human Lymphoma Leukemia”Japan Sci, Soc. Press, Tokyo/VNU Science Press, Utrechtpp. 277-288 (Exhibit 2).
Sandstrom, E.G. and Kaplan, J.C., (1987) “Antiviral Therapy in AIDS: Clinical Pharmacological Properties and Therapeutic Experience to Date”Drugs34:372-390 (Exhibit 3).
Wanda, P.E., and Smith, J.D., (1983) “A General Method for Heterokaryon Detection Using Resonance Energy Transfer and a Fluorescence-activated Cell Sorter”J. Histochem.&Cytochem.30(12):1297-1300 (Exhibit 4).
Sinangil, F. et al, (1988) “Quantitative Measurement of Fusion Between Human Immunodeficiency Virus and Cultured Cells Using Membrane Fluorescence Dequenching”Feb Letters. 239:88-92 (Exhibit 5).
Szabo, G. et al, (1992) “CD4 Changes conformation Upon Ligand Binding” J.Immunol.149:3596-3604 (Exhibit 6).
Peden, K. et al, (1991) “Changes in Growth Properties on Passage in Tissue Culture of Viruses Derived from Infectious Molecular Clones of HIV-1 LAI, HIV-1 MAL, and HIV-1 ELI”Virology, 185:661-672. (Exhibit 7).
Szabo, G. Jr et al. (1993) “Specific Disengagement of Cell-Bound Anti-LAM-1 (Anti-Selectin) Antibodies by Aurintricarboxylic Acid” Molecular Immunology, vol. 30, No. 18. 1689-1694. (Exhibit 2).
Allaway Graham P.
Litwin Virginia M.
Maddon Paul J.
Cooper & Dunham LLP
Parkin J. S.
Progenics Pharmaceuticals Inc.
White John P.
LandOfFree
Methods for using resonance energy transfer-based assay of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for using resonance energy transfer-based assay of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for using resonance energy transfer-based assay of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3489703